ArticlePhysics and imaging in radiation oncology2025
The value of post radiotherapy prostate specific antigen dynamics for prostate cancer risk stratification models.
Article in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Risk-stratification at diagnosis of prostate cancer does not always predict risk of biochemical recurrence (BCR). Fully utilizing post-radiotherapy follow-up Prostate Specific Antigen (PSA) data could offer earlier and higher prognostic value than pre-treatment risk-stratification.We investigate whether PSA dynamics in the first three-years of follow-up can re-stratify risk of treatment failure after radical radiotherapy, allowing for targeted intervention. Materials and methods: Retrospective analysis of repeat follow-up PSA measurements from men with mixed-risk prostate cancer treated in two separate radical radiotherapy techniques (n = 446, 2005-2007). PSA trajectories were modelled between zero and three-years follow-up using Gaussian Process regression. Models were sampled and clustered using hierarchical clustering to define characteristic post-radiotherapy PSA trajectories.Kaplan-Meier analysis compared dichotomising by pre-treatment risk-group and characteristic PSA trajectory. Cox proportional-hazard models with and without follow-up PSA information compared using Akaike Information Criterion (AIC). Results: PSA trajectories were characterized as stable, steady-rise, and unstable. Kaplan-Meier analysis showed that pre-treatment risk-group was not prognostic of BCR (p > 0.05), however characteristic PSA trajectory was (p < 0.001). PSA trajectory improved multivariable model performance when added to baseline prognostic variables. Unstable PSA had highest BCR.Results were validated across two cohorts and sensitivity analysis, suggesting results were robust. However, analysis excluded patients with BCR within three-years follow-up due to lack of data. Conclusion: PSA dynamics within the first three-years of post-radiotherapy follow-up for prostate cancer were more prognostic of BCR than pre-treatment risk-groups, suggesting PSA dynamics could be used to re-stratify BCR risk during early follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.